Before the national holiday winddown, US stocks got a boost on Wednesday with signs of an acceleration in the US economic recovery.

Jobless claims (aka layoffs) fell to the lowest weekly level in 52 years, while household spending and personal income both rose.

Minutes from the Federal Reserve’s November meeting showed officials still expect inflation to ease in 2022, but discussed increasing the pace of tapering, as consumer-price rises may be longer-lasting than previously anticipated.

But now that Wall Street is closed Thursday and Friday for Thanksgiving, focus has redirected to Europe, where the share market has rebounded off three-week lows.

Investors bought into the so-called defensive sector – utilities – as soaring Covid cases across France caused face masks to become compulsory again.

 

How did this week’s IPOs perform?

 

Nimy Resources (ASX:NIM)

Investors in the Simon Lill-chaired company are hoping it can replicate the success of his gold play De Grey Mining (ASX:DEG) in the nickel space.

Nimy’s board also includes executive director Luke Hampson, a resources executive whose family holds ~26% of the listed firm and mining engineer Christian Price, previously the CEO of gold junior Resources and Energy Group (ASX:REZ).

NIM’s main focus is the Mons nickel project in Western Australia, comprising six exploration licences and six applications over 1761km2 of ground.

Nimy was up 7.5% on its 20c offer price on its first day of trade Monday and is currently trading at 22c per share.

 

RAS Technology Holdings (ASX:RTH)

The company, which provides data, enhanced content and SaaS solutions to the global racing and wagering industries, raised $29 million in an IPO at $1.50 per share.

Flagship clients include all the big boys: like Entain Group (including Ladbrokes and Neds), Flutter Group (including Sportsbet, Paddy Power and Betfair), Tabcorp, BlueBet (ASX:BBT) and Bet365.

The company gained 13% on listing on Tuesday, peaked at $1.84 on Thursday and is currently trading at $1.67.

 

EBR Systems (ASX:EBR)

The heart failure medical device company listed on Wednesday, raising $110 million at US$1.08.

EBR Systems has develop an implantable system for wireless tissue stimulation, with its proprietary WiSE Technology designed to eliminate the need for a lead to the left ventricle in Cardiac Resynchronization Therapy (CRT) and the associated complications of that lead.

The company aims to expand its technology into other applications in the $11 billion cardiac rhythm management (CRM) market.

The share price dropped to $1.03 on Thursday before rising 3.84%, and levelling out at $1.05.

 

Radiopharm Theranostics Ltd (ASX:RAD)

The company, which is the latest venture of biotech entrepreneur Paul Hopper, is targeting some of the largest markets in cancer with its radiopharmaceuticals drugs that can either act as a diagnostic, allowing physicians to see and to measure disease within the body, or as a therapeutic where high energy particles are emitted to treat cancer and other diseases.

RAD has four platform technologies which are in five Phase 2 trials and two Phase 1 trials.

The company listed on Thursday, raising $50 million at 60c and is currently trading down a massive 38% at 37c.

 

Artrya Limited (ASX:AYA)

The medical technology company listed today after raising $40 million at $1.35. Its share price is up ~13% to $1.52.

Artrya develops software which automates the analysis of heart computed tomography (CT) scans to assist in the diagnosis of Coronary Artery Disease.

It’s Salix technology is an AI-based solutions which analyses cardiac CT scans to detect a unique combination of heart attack biomarkers and produces a comprehensive patient report in approximately 15 minutes.

Market pilots of Salix are underway in Australia and the company expects a number of the pilot programs will progress to commercial use in the first half 2022.

 

 

ASX SMALL CAP WINNERS:

Here are the best performing ASX small cap stocks for November 22 – November 26 [intraday]:

Swipe or scroll to reveal full table. Click headings to sort:

 

In case you missed it on Stockhead this week, Antiviral biotechnology stock Biotron (ASX:BIT) turned heads  after announcing that its lead drug candidate — BIT225 — had been shown to be effective against COVID-19 in animals.

After tracking from ~8c to below 5c through the course of 2021, BIT shares shot higher by more than 60% at the opening bell yesterday following the update, with shares up 88% this week.

The company “is now in discussions with its USA advisors and consultants to expedite progression of BIT225 into human trials for treatment of SARS-CoV-2 infection”, it said.

Indoor Skydive Australia (ASX:IDZ) jumped 82% this week after announcing on Monday it opened its fourth FREAK entertainment centre in Macquarie shopping centre in Sydney.

The company launched its new motor racing simulator product, FREAK Drive, at the venue, which the company says provides ultra-realistic racing simulation.

IDZ FREAK Drive

Real-time software player Vection Technologies (ASX:VR1) gained a tidy 63% this week, announcing on Tuesday its plans to jump aboard the metaverse bandwagon.

The company unveiled its FrameS ‘Metaverse’ release – in anticipation of becoming an Embedded App within Webex in the second half of FY22.

Vetcion said the release would combine the 3D worlds capabilities of FrameS with Webex’s video conferencing and online meetings tools, allowing organisations to autonomously build self-contained immersive metaverses: enterprise focussed, dynamic 3D worlds where people can participate equally from anywhere in the world.

E2 Metals (ASX:E2M) is up 46%, basking in the glow of a huge gold hit in early drilling at the new ‘Andrea Sur’ discovery, part of the Conserrat project in underexplored Argentina.

The highlight 16m grading 15g/t gold, 22g/t silver intercept came from just 31m depth.

That’s thick, extremely high grade, and shallow – the trifecta for any investor examining precious metals drilling results.

And cannabis player Emyria (ASX:EMD) got a healthy boost when Twiggy Forrest’s investment fund took a stake in the company.

A private fund owned by the Forrest family, Tattarang, has invested $5m or 7.3% stake in the company, with funds expected to be used to accelerate synthetic cannabinoid registration programs with the TGA and FDA, the company said.

The fresh funds will also advance Emyria’s novel MDMA-analogue development program with the University of Western Australia.

The EMD stock price jumped 12% on the news, with the company trading up 42% this week.

ASX SMALL CAP LOSERS

 Here are the worst performing ASX small cap stocks for November 22– November 26 [intraday]:

Swipe or scroll to reveal full table. Click headings to sort:

 

Constellation Resources (ASX:CR1) fell 40% this week after an exploration update from maiden diamond drilling at its Eyre South prospect.

The drilling encountered trace levels of magmatic nickel and copper, and the company has submitted the core for assay with results expected in the March 2022 quarter.

And down 29% was Advanced Human Imaging (ASX:AHI) (formerly known as MyFiziq) after announcing it had closed a US$10.5 Million U.S. Initial Public Offering on the Nasdaq index.

The company also confirmed it had settled two convertible note subscription agreements with Asia Cornerstone Asset Management (ACAM) and iConcept Global Growth Fund “by mutual agreement”.